Skip to main content
Premium Trial:

Request an Annual Quote

Structural Bioinformatics Licenses Database to De Novo

NEW YORK, Nov 21 – Structural Bioinformatics of San Diego said Tuesday it had licensed its SBdBase database of 3-dimensional protein structures to De Novo Pharmaceuticals.

Under the terms of the deal, De Novo will have access to multiple therapeutic target classes, Structural Bioinformatics said in a statement.

Financial terms were not disclosed.

" The combination of SBI's proprietary protein structures with De Novo's powerful proprietary drug design algorithms extends our design platform from experimentally determined protein structures to the broader world of sequence-based information,” David Bailey, De Novo's CEO, said.

“The agreement with SBI will allow De Novo to expand its drug design partnerships with early-stage genomics targets," he said. 

De Novo of Cambridge, UK, uses proprietary computational software for drug design to create lead molecules as candidates for drug development.

De Novo has collaborated with British Biotechnology and Aventis Pharma.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.